Skip to content
- Pharma companies are starting to really come into their own with introducing innovative ways of pricing.
- Alnylam only charges the $575k price for givosiran if the effect seen is on par with clinical trials.
- Novartis now collects the $2.1m price tag for Zolgensma over 5 years.
- Sanofi are offering $99/month subscriptions for insulin.
- Pricing is a big issue for US Pharmaceuticals. There are start-ups looking at this issue as well – Generics 2.0.
- New stats from the US Cancer Society show that between 1991 and 2017 the mortality rate of cancer has dropped 29%.
- According to the report, this was due to lower smoking rates, improved early detection methods and advances in treatment.
- This trend means more than 2.9m lives were saved since 1991.
- Really amazing.
WordPress Cookie Notice by Real Cookie Banner
